A predictive probability design for phase II cancer clinical trials

@article{Lee2008APP,
  title={A predictive probability design for phase II cancer clinical trials},
  author={J. Lee and D. Liu},
  journal={Clinical Trials},
  year={2008},
  volume={5},
  pages={106 - 93}
}
  • J. Lee, D. Liu
  • Published 2008
  • Medicine
  • Clinical Trials
  • Background Two- or three-stage designs are commonly used in phase II cancer clinical trials. These designs possess good frequentist properties and allow early termination of the trial when the interim data indicate that the experimental regimen is inefficacious. The rigid study design, however, can be difficult to follow exactly because the response has to be evaluated at prespecified fixed number of patients. Purpose Our goal is to develop an efficient and flexible design that possesses… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving… Expand
    ConditionsBreast Cancer Metastatic, Chemotherapy-induced Peripheral Neuropathy
    InterventionDrug
    Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials
    • 46
    • Open Access
    A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    • 16
    • Highly Influenced
    A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials
    • 6
    • Open Access
    A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    • 13
    • Highly Influenced
    Controlled multi-arm platform design using predictive probability
    • 20
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 49 REFERENCES
    Optimal two-stage designs for phase II clinical trials.
    • 2,986
    • Open Access
    Admissible two-stage designs for phase II cancer clinical trials.
    • 100
    Optimal three-stage designs for phase II cancer clinical trials.
    • 112
    Optimal flexible designs in phase II clinical trials.
    • 114
    Practical Bayesian guidelines for phase IIB clinical trials.
    • 169
    Bayesian interim analysis of phase II cancer clinical trials.
    • 87
    Randomized phase II designs in cancer clinical trials: current status and future directions.
    • 116